EnAble Therapeutics has informed Chelsea’s Hope that it is willing to partner with clinicians to lead a n=1 Expanded Access trial or through the Right to Try Act with their potential therapy for Lafora Disease, VAL-1221.
EnAble has indicated that the following medical resources and support will be needed:
Clinicians with institutional support including internal and external regulatory assistance and treatment / I.V. infusion capability.
EnAble has confirmed that this could be your child’s primary neurologist but EnAble has also confirmed that the clinician does not need to be a neurologist.
If interested, please have your clinician contact: